trending Market Intelligence /marketintelligence/en/news-insights/trending/tl7j7Sm6EuxvJNsSQD_-fA2 content esgSubNav
In This List

INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

INSYS Therapeutics Inc.'s cannabis treatment to treat the Prader-Willi syndrome received the U.S. Food and Drug Administration's fast track designation.

Prader-Willi syndrome is a rare genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.

The company plans to start clinical development of its oral investigational treatment in the late first quarter of 2018.